The aim of this study was to assess the prognostic performance of C-terminal provasopressin ( copeptin ) , midregional pro-adrenomedullin ( MR-proADM ) , and midregional pro-atrial natriuretic peptide ( MR-proANP ) in a large prospective cohort of patients with non-ST-segment elevation acute coronary syndrome ( NSTE-ACS ) .